Heart failure mystery: why do water pills fail some patients?

NCT ID NCT05323487

Recruiting now Knowledge-focused Sponsor: Yale University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study aims to understand why some heart failure patients do not respond well to diuretics (water pills). Researchers will give 75 heart failure patients different doses of a diuretic called bumetanide and measure how their kidneys handle sodium. The goal is to identify biological markers that predict diuretic resistance, which could help tailor treatments in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Bumetanide
What this could lead to: If successful, this study could help doctors understand why some heart failure patients are resistant to diuretics, potentially leading to better personalized treatment.
What could go wrong: This is an early-phase study with only 75 participants, so results may not apply to all heart failure patients. It is designed to gather knowledge, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE

Contacts and locations

Locations

Yale University
RECRUITING

New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.